ABIN-1 targets β-arrestin-2 to attenuate opioid tolerance

Yixin Zhang, Peilan Zhou*, Fengfeng Lu, Ruibin Su*, Zehui Gong

State Key Laboratory of Toxicology and Medical Countermeasures, Beijing Key Laboratory of Neuropsychopharmacology, Beijing Institute of Pharmacology and Toxicology, 27th Taiping Road, Beijing 100850, China
Running title: ABIN-1 attenuates opioid tolerance and dependence

Yixin Zhang, Peilan Zhou*, Fengfeng Lu, Ruibin Su*, Zehui Gong

Corresponding Author: Ruibin Su

Email: ruibinsu@126.com

State Key Laboratory of Toxicology and Medical Countermeasures, Beijing Key Laboratory of Neuropsychopharmacology, Beijing Institute of Pharmacology and Toxicology, 27th Taiping Road, Beijing 100850, China.

Tel: +861066931621/01; fax: +861068211656.

Corresponding Author: Peilan Zhou

Email: zhoupeilan0502@sina.com

State Key Laboratory of Toxicology and Medical Countermeasures, Beijing Key Laboratory of Neuropsychopharmacology, Beijing Institute of Pharmacology and Toxicology, 27th Taiping Road, Beijing 100850, China.

The number of text pages: 41
The number of text figures: 4
The number of references: 56
Words in the Abstract: 181

Abstract

Opioids play an important role in pain relief, but repeated exposure results in tolerance and dependence. To make opioids more effective and useful, research in the field has focused on reducing the tolerance and dependence for chronic pain relief. Here, we showed the effect of ABIN-1 in modulating morphine function. We used hotplate tests and CPP tests to show that overexpression of ABIN-1 in the mice brain attenuated morphine dependence. These effects of ABIN-1 are most likely mediated through the formation of ABIN-1-β-arrestin2 complexes, which accelerate β-arrestin2 degradation by ubiquitination. With the degradation of β-arrestin2, ABIN-1 overexpression also decreased MOR phosphorylation and internalization following opioid treatment, affecting the β-arrestin2-dependent signaling pathway to regulate morphine tolerance. Importantly, the effect of ABIN-1 on morphine tolerance was abolished in β-arrestin2 knockout mice. Taken together, these results suggest that the interaction between ABIN-1 and β-arrestin2 inhibits MOR internalization to attenuate morphine tolerance, revealing a novel mechanism for MOR regulation. Hence, ABIN-1 may be a therapeutic target to regulate MOR internalization, thus providing a foundation for a novel treatment strategy for alleviating morphine tolerance and dependence.

Key words: MOR; ABIN-1; β-arrestin2; tolerance; dependence
Significance Statement

ABIN-1 overexpression in the mouse brain attenuated morphine tolerance and dependence. The likely mechanism for this finding is that ABIN-1-β-arrestin2 complex formation facilitated β-arrestin2 degradation by ubiquitination. ABIN-1 targeted β-arrestin2 to regulate morphine tolerance. Therefore, the enhancement of ABIN-1 is an important strategy to prevent morphine tolerance and dependence.
Introduction

Opioids, such as morphine, have powerful analgesic effects and are used to relieve acute and chronic pain; however, their repeated or continuous use can result in tolerance and dependence issues. These effects limit the clinical utility of morphine as an analgesic. Opioids act on μ opioid receptor (MOR) to activate G protein-dependent and β-arrestin-mediated signaling (Whalen et al., 2011; Williams et al., 2013). Although super-activation or sensitization of adenylate cyclase (AC) by chronic agonist treatment in the G protein-dependent signaling pathway is considered the classical mechanism of opioid tolerance (Sharma S K 1975), β-arrestin-mediated signaling has also been shown to play an important role in morphine tolerance (A et al., 2019; Allouche et al., 2014; Bohn et al., 2000; Bohn et al., 1999; Kliewer et al., 2019; Li et al., 2009; Whalen et al., 2011; Williams et al., 2013).

β-arrestins, including β-arrestin1 and β-arrestin2, are highly expressed in the central nervous system (CNS) and play critical roles in regulating MOR function (Attramadal et al., 1992; Le Rouzic et al., 2019). Several lines of evidence suggest that β-arrestin expression, especially β-arrestin2, is involved in the internalization of MOR. In mouse embryonic fibroblasts (MEFs), β-arrestin2 is recruited after MOR phosphorylation, which causes a sequestration of MOR following morphine exposure (Groer et al., 2011). In addition, ubiquitinated β-arrestins are crucial for downstream endocytic and signaling processes (Takenouchi et al., 2018). Mice lacking β-arrestin2 did not develop tolerance in a hot plate test following chronic morphine treatment,
suggesting the vital role β-arrestin2 plays in MOR regulation (Sadat-Shirazi et al., 2019). Several proteins mediate morphine tolerance by regulating β-arrestin2. For example, TRPV1 promoted rapid translocation of β-arrestin2 to the nucleus and decreased the desensitization of MOR, which enhanced the analgesic effect (Basso et al., 2019). Likewise, the vasopressin 1b receptor enhanced morphine analgesia by modulating the interaction between β-arrestin2 and MOR (Koshimizu et al., 2018). Additionally, MiR-365 mediated downregulation of β-arrestin2 reduced the antinociceptive tolerance to morphine (Wu et al., 2018). Recently, MOR-associated proteins that negatively regulate the β-arrestin2 signaling pathway are being considered as therapeutic targets and molecular probes to resolve issues regarding chronic opioid use. Notably, studies have shown the feasibility and potential clinical utility of biased MOR agonists such as PZM21 and TRV130 (Manglik et al., 2016). A20-binding inhibitor of NF-κB (ABIN-1) is well known as a ubiquitin-binding protein that plays an important role in autoimmune inflammatory diseases, such as systemic lupus erythematosus and psoriasis, by its inhibitory action on NF-κB activation (Heyninck et al., 2003; Nanda et al., 2011). ABIN-1 has also been shown to bind to ERK2 and suppress ERK2 entering into the nucleus (Zhang, 2002). In our previous study, we found that ABIN-1 functionally interacted with MOR and was upregulated in morphine-tolerant mice. ABIN-1 negatively regulated MOR function by inhibiting the phosphorylation and signaling of ERK2. Our results suggest that ABIN-1 negatively regulates MOR function and may be a potential target for the development of novel therapeutic strategies for opioid tolerance.
not clear. Thus, further studies should focus on determining the mechanism of ABIN-1 actions on morphine tolerance and dependence.

In the current study, we discovered that ABIN-1 in the mouse brain attenuated morphine dependence and tolerance. The interaction between ABIN-1 and β-arrestin2 increased the ubiquitination of β-arrestin2, which led to the degradation of β-arrestin2 and the reduction of MOR internalization. Additionally, we found that ABIN-1 overexpression or knockdown in β-arrestin2-knockout mice did not affect morphine antinociceptive tolerance. Overall, our results show a mechanism by which ABIN-1 acts on β-arrestin2 to regulate morphine tolerance.
Materials and Methods

Animals

We used C57BL/6J mice aged 8 weeks (18–22 g) for all the experiments in our study. The hot plate test was conducted on the female mice, and the conditioned place preference (CPP) test was conducted on the male mice. Female β-arrestin2-knockout (ARRB2−/−) mice, obtained from the laboratory of R. J. Lefkowitz (Duke University Medical Center, Durham, NC), were backcrossed onto a C57BL/6J background. All animals were housed under temperature- and humidity-controlled conditions on a 12-h light/12-h dark cycle with free access to food and water. Animals were assigned into different treatment groups in a random manner. The experimental procedures were reviewed and approved by the Ethics Committee and Institutional Animal Care and Use Committee of Beijing Institute of Pharmacology and Toxicology, Beijing, China (IACUC of AMMS--06--2018--020). All efforts were made to minimize suffering and reduce the number of animals used.

Reagents

Drugs: [D-Ala2, N-MePhe4, Gly-ol]-enkephalin (DAMGO) and naloxone were obtained from Sigma-Aldrich, and morphine hydrochloride was obtained from Qinghai Pharmaceutical Factory.

Behavioural tests
Viral constructs and Stereotaxic microinjection

AAV2/9 viral vectors were designed and constructed using standard methods with assistance from BrainVTA (Wuhan, China). rAAV-CMV-ABIN-1-EGFP-WPRE-pA (AAV/PHPeB, titer: ≥ 3.0E+12 vg/ml) and rAAV-U6-shRNA (ABIN-1)-CMV-EGFP-pA (AAV/PHPeB, titer: ≥ 5.0E+12 vg/ml) were administrated through intracerebroventricular (i.c.v.) injection in the brain. C57BL/6J mice were anaesthetized using xyz for stereotaxic viral injections. Viruses were unilaterally injected into the right cerebral ventricle (AP = −0.6 mm, ML = 1.5 mm, DV = 2.0 mm, 5 µl, 0.5 µl/min).

Hot plate test

Morphine (10 mg/kg, s.c.) antinociception was assessed according to a protocol described in the literature (Eddy and Leimbach, 1953). Female mice were placed on the surface of the hot plate (55°C). The latency to jump and lick the hind paws was recorded from the start time for each mouse. A cut-off time of 60 seconds was used to prevent the possibility of tissue damage. Antinociceptive data are presented as a percentage of the maximal possible effect (% MPE) calculated by the following formula: % MPE = (post drug latency – pre drug latency) / (60 – pre drug latency) × 100%.

Naloxone-precipitated withdrawal

Mice were administered morphine (10 mg/kg, s.c., twice daily) for seven days. The
antinociception effect of morphine was detected in the morning from day 1 to day 7. On day 7, mice were administrated naloxone (10 mg/kg, i.p.) two hours after the last injection of morphine and then individually placed in Plexiglas boxes (60 cm × 20 cm × 20 cm) to observe the withdrawal signs: jumping, wet dog shaking, and paw tremor for 15 min.

Conditioned place preference test

We assessed psychological dependence on morphine in our mice using a morphine conditioned place preference (CPP) test. The CPP test was performed using an unbiased, counterbalanced protocol (Wang et al., 2008). The CPP apparatus contained eight identical three-chamber polyvinyl chloride (PVC) boxes (Lu et al., 2011). The two large compartments were different with white walls and a bare floor in one compartment, and black walls with a gridded floor in the second compartment, which provided distinct context pairing with morphine and saline administration. The three compartments were connected by manual guillotine doors. The CPP test paradigm is outlined in Fig 1D. During the pre-conditioning period (from day 1 to day 3), male mice were free to move in all chambers of the apparatus for 15 min. The time spent by the mice in each chamber was recorded (AniLab v3.0, AniLab Software & Instrument Co. Ltd., Ningbo, China). Mice that showed a strong unconditioned preference (more than 540 seconds) for either compartment were excluded from the experiment such that our sample mouse population did not have an innate preference for one chamber. Mice underwent conditioning training (day 4 to day 8) for five days. During the
conditioning phase, mice were administered normal saline (N.S, 10 ml/kg, i.p.) in the morning and morphine (10 mg/kg, s.c.) in the afternoon followed by 30 min of training. The CPP test was conducted on the ninth day. The CPP score was calculated as the time (in seconds) spent in the drug-paired chamber after conditioning minus the time spent in the drug-paired chamber before conditioning.

Locomotor activity

We used the LabState video tracking system (Anilab Scientific Instruments Co., Ltd., China) to measure spontaneous locomotor activity. The mice were placed in acrylic boxes (40 cm × 40 cm × 35 cm) for 30 min before morphine treatment on day 1. Mice were habituated for 1 hr before being placed in an open field. The locomotor activity of each mouse was defined by the horizontal distance it travelled (in centimetres) over 30 min.

Cell culture and transfection conditions

HEK293 cells were cultured in DMEM (Thermo Fisher Scientific) containing 10% FBS (v/v, Sigma-Aldrich). CHO cells stably expressing Flag-MOR (MOR-CHO) were grown in F12 (Thermo Fisher Scientific) medium containing 10% FBS and supplemented with G418 (200 µg/ml) (Thermo Fisher Scientific). CHO cells stably expressing Flag-MOR and Myc-ABIN-1 (MOR-ABIN-1-CHO) were grown in F12 medium containing 10% FBS and supplemented with G418 (200 µg/ml) and hygromycin B (200 µg/ml). Neuro-2A (N2A) cells were grown in DMEM containing
10% FBS. All cells were cultured at 37°C in a humidified atmosphere at 5% CO₂. Transient transfections were carried out using Lipofectamine 3000 (Invitrogen) with cells grown to 65–85% confluency.

Coimmunoprecipitation

HEK293 cells in 10-cm dishes were co-transfected with the plasmid using Lipofectamine 3000 for 48 hrs. Next, the cells were lysed immediately with EBC buffer (50 mM Tris-HCl [pH 8.0], 120 mM NaCl, 0.5% NP-40, and 1 mM EDTA) and a protease inhibitor mixture (Roche Applied Science) for 30 min on ice. The cells were centrifuged at 14,000 × g at 4°C for 20 min. The supernatant was divided into three parts: one part was denatured by incubating in boiling water for 10 min. The remaining supernatant was divided into two parts: 1 μg of anti-Flag antibody was added to one part, and 1 μg of IgG with the same properties was added to the other part. Both were kept on a shaker at 4°C overnight. Then, 30 μl of protein G magnetic beads (Thermo Fisher Scientific, Cat#88847) was added for 2 hrs at 4°C. Following three washes with EBC buffer, the protein was eluted with 50 μl of 1× SDS sample buffer for 10 min at 95°C.

Phosphorylation of MOR and ERK

MOR-CHO and MOR-ABIN-1-CHO cells were serum starved for two hrs prior to drug treatment. Cells were treated with DAMGO for 0 min, 5 min, 30 min, 60 min, 6 h, 24 h, 48 h, and 72 h and then lysed with lysis buffer (50 mM Tris-HCl [pH 7.4],
150 mM NaCl, 5 mM EDTA, 10 mM NaF, 10 mM disodium pyrophosphate, 1% Nonidet P-40, 0.5% sodium deoxycholate, protease inhibitor mixture and 0.1% SDS); they were then treated with phos-STOP phosphatase inhibitor (Roche) on ice for 30 min. The lysate was centrifuged at 14,000 × g for 20 min at 4°C. The supernatant was separated by SDS-PAGE, and immunoblot analysis was performed using anti-phos-MOR or anti-phos-ERK.

β-arrestin2 ubiquitination assay

pcDNA3.1myc-hisB-ABIN-1, pCMV-Flag-β-arrestin2 and pcDNA3.1-MOR were transiently transfected into HEK-293 cells for 24 h. Cells were serum starved for at least 2 h and then stimulated with DAMGO for 30 min. Next, cells were solubilized in lysis buffer (50 mM Tris-HCl [pH 8.0], 150 mM NaCl, 5 mM EDTA, 0.1% SDS, 10% glycerol, 1% Nonidet P-40, 0.5% deoxycholate, 10 mM sodium orthovanadate, 10 mM NaF, and 10 mM N-ethylmaleimide) with a protease inhibitor mixture. Cell lysates were mixed with FLAG M2 affinity beads (Sigma-Aldrich) and rotated at 4°C overnight. The precipitate was washed three times in lysis buffer, and the protein was eluted with 50 μl of 2 × loading buffer and analysed by SDS-PAGE.

Internalization of MOR

The plasma membrane protein fraction of both cells and brain tissue was separated by a plasma membrane protein isolation kit (Invent Biotechnologies) to determine the internalization of MOR. Cells or tissue in buffer A was placed on ice for 5-10 min and
was then centrifuged at 16,000 × g for 30 s. The supernatant was discarded, and the pellet was resuspended by vigorous vortexing for 10 s. The resulting suspension was centrifuged at 700 × g for 1 min. The supernatant was transferred to a fresh 1.5 ml microcentrifuge tube and centrifuged at 16,000 × g for 30 min at 4°C. The supernatant was removed, and the pellet (the total membrane protein fraction including organelles and plasma membranes) was retained. The total membrane protein fraction was resuspended in 200 µl of buffer B by repeatedly pipetting up and down or vortexing. The resulting suspension was centrifuged at 7,800 × g for 5 min at 4°C and the supernatant was removed. Ice-cold PBS (1.6 ml) was added and centrifuged at 16,000 × g for 30 min at 4°C. The isolated plasma membrane proteins in the pellet were retained and then separated by SDS-PAGE.

Confocal immunofluorescence

HEK293 cells were seeded into 35-mm cell culture dishes with coverslips attached and then transfected with pcDNA3.1myc-hisB-ABIN-1 and pEGFP-N3-β-arrestin2 using Lipofectamine 3000, as mentioned above. Immunocytochemistry was performed as previously described (Zhou et al., 2015). Next, cells were fixed with 4% paraformaldehyde for 30 min, after which the fixed solution was aspirated and washed three times with PBS for 3 min each time. These cells were then incubated in 0.5% Triton X-100 in PBS for 20 min at room temperature and washed three times in 1 × PBS. Cells were blocked for 30 min (1% BSA), washed with PBST, incubated with the primary anti-myc antibody (Abcam, 1:200) at 4°C overnight, and washed three
times in 1× PBST. Finally, the cells were incubated with rhodamine-conjugated Affinipure goat anti-mouse IgG antibody (1:100; Santa Cruz) for 1 hr at room temperature. Cells were then washed and treated with DAPI Fluoromount-GTM (VECTOR) for 5 min at room temperature in the dark and then mounted onto glass slides. The cells were examined using a laser-scanning Zeiss LSM510 confocal microscope.

Statistical analysis

Statistical analyses were performed using GraphPad Prism 7.0 software (GraphPad Software Inc., La Jolla, CA, USA). The results are expressed as the mean ± SD. The effect of ABIN-1 viral vector injection in the brain or the cell assay was analysed using two-way analysis of variance (ANOVA) followed by the Bonferroni post-hoc test. The naloxone precipitation test was analysed using one-way analysis of variance (ANOVA) followed by the Bonferroni post-hoc test. The criterion for statistical significance was set at $P < 0.05$ for all analyses.
Results

ABIN-1 attenuates morphine-induced tolerance and dependence

To investigate the role of ABIN-1 in morphine-induced tolerance and dependence, we infused rAAV(PHPeB)-ABIN-1 by i.c.v. injection to upregulate ABIN-1 levels in the mice brain. The antinociception induced by morphine was assessed by hot plate test 21 days after viral infusion (rAAV(PHPeB)-vector [control], rAAV(PHPeB)-ABIN-1) in mice and wild type (WT) mice (Fig 1A). ABIN-1 was overexpressed in the CNS, specifically in the hippocampus, as observed via immunoblot analysis and immunofluorescence (Suppl 1A). Prior to morphine treatment, the locomotor behaviour of the mice were similar among the three groups of mice (Suppl 1D), and the basal nociceptive latencies in the ABIN-1 overexpression group were also similar to that of control and WT from days 1 to 7 (Suppl 1E).

The %MPE of the ABIN-1 upregulated group decreased gradually following chronic morphine treatment (10 mg/kg, s.c.). However, the %MPE differed between the control group and ABIN-1 upregulated group after morphine treatment. The %MPE in the ABIN-1 overexpression group was higher than the control group following morphine exposure on days 1, 3, and 5 (Day 1: \( P = 0.0194 \), Day 3: \( P = 0.0051 \), Day 5: \( P = 0.0325 \); F (1, 7) = 71.75, \( P < 0.0001 \), Fig 1B).
curve (AUC) was calculated by hotplate test data and used as the quantitative indicator for antinociceptive effects of drugs. ABIN-1 overexpression augmented the value of AUC, showing that ABIN-1 increased morphine analgesia with a decreased morphine tolerance after chronic morphine treatment (ABIN-1 versus control; 150.6±11.86 versus 88.38±17.45). We also analysed naloxone-induced (10 mg/kg, i.p.) withdrawal response following chronic morphine treatment. Similar to inhibition of morphine-induced antinociceptive tolerance by ABIN-1 overexpression, ABIN-1 decreased naloxone-precipitated jumping behaviour, the most sensitive and reliable index of withdrawal related to physical dependence on morphine (el-Kadi and Sharif, 1994) ($P = 0.0212$, Fig 1C), but had no effect on paw tremor and wet dog shaking (Suppl 1H). To investigate whether ABIN-1 would affect the psychological dependence on morphine, the CPP test was conducted in four groups of mice with viral infusion (as mentioned above) as well as in WT mice (with solvent, morphine addition) (Fig 1D). The baseline CPP score between the ABIN-1 overexpression group and the control group was not different statistically. After five days of conditioning, the mice in the control group, as well as in the WT group, showed a clear preference for the morphine-paired compartment ($P = 0.0414$). In contrast, mice in the ABIN-1 overexpression group did not prefer the white box. The CPP was inhibited in ABIN-1 overexpression mice in comparison with the control group ($P = 0.0159$, Fig 1E). The mice with solvent treatment also preferred the black compartments without CPP.
Next, we tested antinociception tolerance as well as physical and psychological dependence induced by morphine treatment on ABIN-1 knockdown mice. ABIN-1 was downregulated by micro-infusion of rAAV(PHP.eB)-ABIN-1-shRNA in the brain (Suppl 1C). Prior to morphine treatment, the mice locomotor behaviour on day 1 and nociceptive latencies from days 1 to 7 in the ABIN-1 knockdown group, the control and the WT group were similar (Suppl 1F-G). Compared with the control group, the %MPE in the ABIN-1 knockdown group was decreased after morphine administration on days 1, 3, and 5 (Day 1: $P = 0.0032$, Day 3: $P = 0.0004$, Day 5: $P = 0.0156$, $F(1, 7) = 15.39$, $P < 0.0044$, Fig 1F). Similar to the AUC result for ABIN-1 overexpression, ABIN-1 knockdown decreased the AUC to reduce morphine analgesia after chronic morphine treatment (sh-ABIN-1 versus control; 75.61±12.01 versus 131.6±22.02). The antinociception in the control group had no obvious difference from the WT group after morphine chronic addition. In the naloxone withdrawal test, there was a augmentation in jumping behaviour ($P = 0.0059$, Fig 1G) and wet dog shaking ($P = 0.0107$, Suppl 1I) in the mice precipitated by naloxone in the ABIN-1 knockdown group compared with the control group), but ABIN-1 knockdown had no effect on paw tremor (Suppl 1I). To confirm the role of ABIN-1 in morphine analgesia, we used AAV-ABIN-1-shRNA to decrease ABIN-1 expression in mice brains for two weeks and then reversed expression of ABIN-1 by AAV-ABIN-1 for two weeks. Following restoration of ABIN-1 expression in ABIN-1 knockdown mice, the effect of ABIN-1 knockdown on morphine analgesia was blocked and the mice
almost recovered similar to the WT mice, demonstrating ABIN-1 expression in mice brains is involved in morphine analgesia (Day 1: \(P = 0.0146\), Day 3: \(P = 0.1071\), Day 5: \(P = 0.0078\), Day 7: \(P = 0.2930\), \(F (1, 8) = 11.94, P = 0.0086\), Suppl 2). In the CPP test, as seen in the previous experiment, the mice in the control group showed a clear preference for the morphine-paired compartment after five days of conditioned training (\(P = 0.035\)). Importantly, compared with the control group, the CPP score in the ABIN-1 downregulated group was higher than the score in the control group (\(P = 0.0302\), Fig 1H). Taken together, these results suggested that ABIN-1 in the brain attenuated antinociceptive tolerance and dependence induced by morphine treatment.

**ABIN-1 promotes β-arrestin2 ubiquitination and degradation by protein interaction**

Previous studies have shown that β-arrestin2 plays an important role in morphine tolerance (Bohn et al., 2002; Bohn et al., 2000); thus, we suspected that ABIN-1 may affect morphine tolerance through β-arrestin2. Therefore, we explored the relationship between ABIN-1 and β-arrestin2. First, the interaction between ABIN-1 and β-arrestin2 was determined by immunofluorescence and co-immunoprecipitation experiments in HEK293 cells. Confocal microscopy revealed that myc-tagged ABIN-1 and GFP-β-arrestin2 were predominantly distributed in the cytoplasm close to the membrane in HEK293 cells. Due to the co-expression of the two proteins, ABIN-1 and β-arrestin2 overlapped, as displayed by the orange color in HEK293 cells (Fig 2A). We found that there was a strong correlation between ABIN-1 and
β-arrestin2 (R = 0.74) in HEK293 cells. The association between ABIN-1 and β-arrestin2 was further investigated by co-immunoprecipitation. β-arrestin2 was immunoprecipitated using a monoclonal anti-Flag antibody from the lysate of HEK293 cells transiently co-transfected with pcDNA3.1-myc-hisB-ABIN-1 (with transfection of pcDNA3.1-myc-hisB in control group), pCMV-Flag-β-arrestin2 (with pCMV-Flag in control cells) and pcDNA3.1-MOR. The immunoprecipitate was immunoblotted with antibodies against ABIN-1. ABIN-1 was found in the immunoprecipitate from cells that co-expressed ABIN-1 and β-arrestin2 (Fig 2B). The interaction of ABIN-1 and β-arrestin2 increased following DAMGO (10 µM) treatment. The interaction of the ABIN-1 and β-arrestin2 was also studied in Neuro 2A (N2A) cells, which have endogenous ABIN-1 and β-arrestin2 proteins. As shown in Fig. 2C, β-arrestin2 was immunoprecipitated from the lysate of N2A cells using anti-β-arrestin2 antibodies. The immunoprecipitate were immunoblotted with antibodies against ABIN-1. ABIN-1 was found to interact with β-arrestin2 by co-immunoprecipitation. Then, β-arrestin2 ubiquitination was analyzed by co-immunoprecipitation in the HEK293 cells as mentioned above. In comparison with the control group, ubiquitination of β-arrestin2 was up-regulated by ABIN-1 overexpression with or without DAMGO (10 µM) treatment (0 min: P = 0.0078, 30 min: P = 0.0361, F (1, 4) = 20.81, P = 0.0103, Fig 2D). Ubiquitin was originally identified as a tag for protein degradation. We measured the effect of ABIN-1 overexpression on β-arrestin2 levels in the N2A cell lines that had stable expression of
β-arrestin2. ABIN-1 was overexpressed in N2A cells by transient transfection with pcDNA3.1-myc-hisB-ABIN-1 (with pcDNA3.1-myc-hisB as control). We found that β-arrestin2 was notably decreased with or without treatment with DAMGO for 30 min (10 μM) compared with its level in control cells (0 min: \( P = 0.0122 \), 30 min: \( P = 0.0444 \), \( F (1, 4) = 40.44, \ P = 0.0031 \), Fig 2E). These data suggested that ABIN-1 decreased β-arrestin2 expression by interaction.

**ABIN-1 decreases the phosphorylation and internalization of MOR**

β-arrestin2 is associated with MOR phosphorylation and internalization (Shukla et al., 2011). We investigated the level of MOR phosphorylation at Ser375 (Schulz S, 2004) (phos MOR) following acute and chronic opioid treatment. We noted that in MOR-CHO cells, the phosphorylation of MOR increased after DAMGO (10 μM) treatment for 5 min followed by a decrease in the phosphorylation following 30 and 60 min of treatment. However, in MOR-ABIN-1-CHO cells, the increase in MOR phosphorylation was inhibited following DAMGO (10 μM) treatment at 5, 30, and 60 min compared with the MOR phosphorylation in MOR-CHO cells (0 min: \( P > 0.9999 \), 5 min: \( P = 0.0064 \), 30 min: \( P = 0.4320 \), 60 min: \( P = 0.0465 \), \( F (1, 2) = 11.34, \ P = 0.0780 \), Fig 3A). Following 24 to 72 h of DAMGO treatment, MOR phosphorylation was upregulated in MOR-CHO cells. In contrast, MOR phosphorylation decreased with ABIN-1 overexpression in MOR-ABIN-1-CHO cells following chronic DAMGO exposure for 24 to 72 h in comparison with its phosphorylation in MOR-CHO cells (0 min: \( P > 0.9999 \), 24 h: \( P = 0.0124 \), 48 h: \( P = 0.0124 \).
Studies have shown that phosphorylated MOR recruits β-arrestin2 to the plasma membrane, which triggers the internalization of MOR (Groer et al., 2011). We extracted MOR in the membrane from MOR-CHO and MOR-ABIN-1 CHO cells. In MOR-CHO cells, the MOR in the membrane was decreased following acute (0 min: MOR-CHO vs. 30 min: MOR-ABIN-1-CHO: \( P < 0.0001 \)) or chronic (0 min: MOR-CHO vs. 72 h: MOR-ABIN-1-CHO: \( P < 0.0001 \)) DAMGO (10 μM) treatment. In contrast, MOR in the MOR-ABIN-1-CHO cells membrane did not decrease following DAMGO treatment for 30 min or 72 h. The MOR in these two time points was higher than in the MOR-CHO cells at the same two time points (Fig 3C). These data show that ABIN-1 inhibited the internalization of MOR after acute or chronic DAMGO exposure (30 min: MOR-CHO vs. 30 min: MOR-ABIN-1-CHO: \( P = 0.0002 \), 72 h: MOR-CHO vs. 72 h: MOR-ABIN-1-CHO: \( P = 0.0002 \), \( F (1, 4) = 11.67, P = 0.0269 \), Fig 3C). Along with the internalization of MOR, we also investigated the β-arrestin-related ERK activity in MOR-CHO and MOR-ABIN-1-CHO cells. Similar to MOR phosphorylation, ERK phosphorylation increased in MOR-CHO cells following 5 min treatment with DAMGO (10 μM), with a time-dependent decrease in phosphorylation at 30 and 60 min. In MOR-ABIN-1-CHO cells, the increase in ERK phosphorylation attenuated following DAMGO (10 μM) treatment at 5, 30, and 60 min compared with MOR-CHO cells at these time points (0 min: \( P > 0.9999 \), 5 min: \( P = 0.0012 \), 30 min: \( P = 0.2667 \), 60 min: \( P = 0.0057 \), \( F (1, 2) = 9.576, P = 0.0905 \), Fig 3C).
Following 24 h of DAMGO treatment, ERK phosphorylation was upregulated in MOR-CHO cells. In contrast, ERK phosphorylation was inhibited in MOR-ABIN-1-CHO cells following DAMGO treatment for 24 and 72 h (0 min: $P = 0.4509$, 5 min: $P = 0.0035$, 24 h: $P = 0.0084$, 48 h: $P > 0.9999$, 72 h: $P = 0.0136$, $F (1, 2) = 43.23$, $P = 0.0224$, Fig 3B). These findings indicated ABIN-1 could regulate the β-arrestin dependent pathway.

**β-arrestin2 is responsible for morphine tolerance mediated by ABIN-1**

Previous studies found that morphine tolerance was attenuated in β-arrestin2-knockout (ARRB2−/−) mice (Bohn et al., 2002; Bohn et al.; Lam et al., 2011). As we observed in the above experiments, the expression of β-arrestin2 is suppressed by interaction with ABIN-1; hence, we wanted to test whether β-arrestin2 is the key target of ABIN-1 to modulate morphine tolerance. Using ARRB2−/− mice, we provided i.c.v injections of rAAV (PHPeB)-ABIN-1 or rAAV(PHPeB)-ABIN-1-shRNA (with rAAV(PHPeB)-vector injected in control group) to upregulate or downregulate ABIN-1, respectively. Wild type (WT) mice were also used in the chronic morphine treatment test as another control. In the chronic morphine-induced tolerance test, the basal nociceptive latencies were similar in ARRB2−/− mice, with ABIN-1 overexpression or ARRB2−/− mice with ABIN-1 knockdown compared with these latencies in the control group (Fig 4A-B). Likewise, in ARRB2−/− mice in which ABIN-1 was overexpressed, the %MPE was the same as in the control group on days 1 to 7 of morphine treatment (10 mg/kg, s.c.) (WT vs
ARRB2−/− Control: Day 1: \( P = 0.0025 \), Day 3: \( P = 0.0001 \), Day 5: \( P = 0.0596 \), Day 7: \( P > 0.9999 \), \( F(1, 4) = 46.92 \), \( P = 0.0224 \); ARRB2−/− Control vs ARRB2−/− ABIN-1: Day 1: \( P > 0.9999 \), Day 3: \( P > 0.9999 \), Day 5: \( P > 0.9999 \), Day 7: \( P > 0.9999 \), \( F(1, 4) = 0.005104 \), \( P = 0.9465 \), (Fig 4C). Similarly, the %MPE values did not change statistically as compared with the control group in the ARRB2−/− mice with downregulated ABIN-1 levels (WT vs ARRB2−/− Control: Day 1: \( P = 0.0014 \), Day 3: \( P < 0.0001 \), Day 5: \( P = 0.1188 \), Day 7: \( P > 0.9999 \), \( F(1, 5) = 23.75 \), \( P = 0.0046 \); ARRB2−/− Control vs ARRB2−/− sh-ABIN-1: Day 1: \( P > 0.9999 \), Day 3: \( P > 0.9999 \), Day 5: \( P > 0.9999 \), Day 7: \( P > 0.9999 \), \( F(1, 5) = 0.01734 \), \( P = 0.9004 \), (Fig 4D). These data suggested that ABIN-1 affected morphine tolerance through β-arrestin2.
Discussion

MOR is widely distributed in the mesolimbic dopamine circuitry and is involved in the modulation of pain and addiction (Serafini et al., 2020). Many opioid receptor-interacting proteins regulate the signal transduction pathways of MOR that modulate the effects of opioids (Georgoussi et al., 2012; Sakloth et al., 2020). In our previous study, the MOR-interacting protein Hsp90β was shown to positively regulate MOR function, and the Hsp90β inhibitor decreased the tolerance and dependence induced by morphine (Zhang et al., 2020). ABIN-1 is mainly expressed in human peripheral blood lymphocytes, the spleen, and skeletal muscle and plays an important role in regulating immunity (Nanda et al., 2011). However, few studies have investigated the role it plays in the nervous system. Our previous study confirmed that the association of ABIN-1 and MOR negatively regulated MOR function in CHO cells and zebrafish larvae (Zhou, 2017). In current study, we found that ABIN-1 modulated the behavioural response following morphine administration. Using adeno-associated virus, we first observed that ABIN-1 overexpression in the mouse brain attenuated morphine-induced tolerance and dependence. The effect of ABIN-1 on morphine tolerance was inhibited in β-arrestin2-deficient mice. This behavioral effect of ABIN-1 on morphine tolerance was associated with β-arrestin signaling via MOR. Indeed, our findings established ABIN-1 as a key regulator of morphine-mediated tolerance, providing keen insights into its functions (Fig 1).
These behavioral effects of ABIN-1 on morphine dependence were detected by the hot plate and CPP assay through adeno-associated virus injection into the cerebral ventricles. Although AAV(PHeB) can efficiently pass through the blood-brain barrier, AAV(PHeB)-ABIN-1-EGFP was not expressed in the whole brain by i.c.v administration. As the AAV(PHeB)-ABIN-1-EGFP has shown (Supp 1A), ABIN-1 and ABIN-1-shRNA were mainly expressed in the hippocampus. ABIN-1 in hippocampus might be involved in morphine tolerance and dependence. Previous studies have shown that the hippocampus contributes to morphine tolerance and withdrawal signs (Eitan S 2003; Koob and Volkow, 2010). Early studies showed that a partial hippocampectomy could treat chronic pain in humans (Jarrard and Lewis, 1967). Additionally, studies show that hippocampal formation can modify the processing of nociceptive information including morphine-induced antinociception (Hashemi et al., 2010; Soleimannejad et al., 2006). Another recent study found that the ventral hippocampal CA1-infralimbic cortex modulates the progression of chronic pain in rats (Ma et al., 2019). Importantly, both MOR and ABIN-1 are widely expressed in the hippocampus (Ferreira-Chamorro et al., 2018), which suggests that they might interact with each other to play a role in hippocampal processing of pain sensations. Our results showed that the change of ABIN-1 expression in the mouse hippocampus modulated the antinociception and withdrawal behaviour induced by morphine treatment. Thus, the hippocampus might be important for the effects of ABIN-1 on morphine function. Reward centers of the brain are related to morphine
analgesia (Watanabe and Narita, 2018), and further research is needed to understand the effect of ABIN-1 on specific brain regions, like Nac or ACC, in pain processing.

Studies have shown that ABINs act as ubiquitin adaptors (Zhou, 2011). In our study, we also found that the ABIN-1-β-arrestin2 complex could promote β-arrestin2 degradation by ubiquitination (Figs 2). β-arrestin2, as a multifunctional adaptor, mediates MOR trafficking and transduction to affect morphine tolerance. Downregulation of β-arrestin2 plays a vital role in MOR desensitization (Jean-Charles et al., 2016). MOR is phosphorylated and ubiquitinated and then follows arrestin-mediated internalization (Mittal and McMahon, 2009). Importantly, MOR activated by morphine only recruits β-arrestin2 (Groer et al., 2011). In the present study, we observed a notable reduction in MOR phosphorylation under acute or chronic MOR agonist treatment (Fig 3A-B). Two lines of evidence may explain why ABIN-1 decreased agonist-induced MOR phosphorylation. First, our previous work showed that ABIN-1 interacted with the MOR-C-terminus, which has several phosphorylation sites. MOR phosphorylation is required for sustained interaction with GRKs under agonist activation (Inagaki et al., 2015). ABIN-1 may compete with GRKs to decrease MOR phosphorylation. Second, the ABIN-1-β-arrestin2-MOR complexes might produce strong steric hindrance to inhibit the function of GRKs. In mice with a series of serine- and threonine- to alanine-mutants of MOR, the opioid-induced antinociception is enhanced and analgesic tolerance is greatly inhibited, which further shows the phosphorylation-deficient MOR in mice inhibits
antinociception tolerance induced by morphine (Kliewer et al., 2019). Our study shows that ABIN-1 mediated reduction of MOR phosphorylation and promoted β-arrestin2 degradation may likely be involved in modulating morphine tolerance.

β-arrestins regulate the internalization of many GPCRs including opioid receptors. It has been observed that both MOR phosphorylation and β-arrestin2 expression are related to MOR endocytosis. Specifically, the reduction of MOR phosphorylation and β-arrestin2 expression lead to a decrease in MOR internalization (Basso et al., 2019; Groer et al., 2011). In our study, higher ABIN-1 levels led to a decrease in β-arrestin2 levels and MOR phosphorylation. This in turn inhibited internalization of MOR (Fig 3C). Classical theory states that reduced MOR on the plasma membrane alters the normal signaling response to opioids, which in turn results in morphine tolerance. Thus, we found that ABIN-1 negatively regulated the β-arrestin signaling pathway, causing less internalization of MOR on the plasma membrane, which then attenuated morphine-induced tolerance.

β-arrestins also act as scaffold-specific components of the mitogen-activated protein kinase (MAPK) cascade (Luttrell et al., 2001). Inhibition of the MAPK pathway blocks desensitization of MOR signaling and decreases the internalization of MOR(Polakiewicz, 1998). ERK1/2, members of the MAPK family, are crucial regulators of MOR signal transduction(Zheng et al., 2008). In our current study, we observed that ERK phosphorylation was inhibited by ABIN-1 under both acute and chronic morphine treatment (Fig 3A-B). As a downstream molecule in both the G
protein- and β-arrestin-dependent pathways (Muller and Unterwald, 2004), the decrease in ERK activation by ABIN-1 is relevant to both pathways. In addition, ABIN-1 could act as an attenuator of activated ERK signaling by interaction with ERK (Zhang, 2002).

A previous study showed that morphine tolerance is reversed and the severity of antagonist-precipitated withdrawal signs is attenuated after chronic morphine exposure in β-arrestin2 knockout mice (Bohn et al., 2002; KM and LM, 2011; Wang et al., 2016). These studies have shown that β-arrestin2 plays an important role in morphine tolerance and dependence. In our study, ABIN-1 had no effect on morphine tolerance in β-arrestin2-KO mice (Fig 4), which suggests that ABIN-1 may alleviate morphine tolerance through down-regulation of β-arrestin2 expression. Additionally, it has been reported that A20, the interacting protein of ABIN-1, attenuated morphine tolerance (Huang et al., 2019) and enhanced MOR function by inhibiting β-arrestin2 recruitment (Shao et al., 2020). Therefore, ABIN-1 and A20 may work together to participate in mediating morphine tolerance.

In summary, we found that the ABIN-1-β-arrestin2 complex functionally diminished MOR phosphorylation and β-arrestin2 expression, which led to a reduction in MOR internalization. Through this mechanism, ABIN-1 overexpression in the mouse brain alleviated morphine tolerance and dependence. This finding was further confirmed by our observation that the therapeutic effect of ABIN-1 on morphine tolerance was blocked in β-arrestin2-KO mice. Overall, we found that
ABIN-1 attenuated morphine-induced tolerance and dependence, which is an important finding that can be used as a potential strategy to improve the therapeutic profile of opioids.
Acknowledgments

We would like to give our sincere appreciation to the National Natural Science Foundation (81473194) for their financial help. We would like to thank Accdon (www.accdon.com) for providing linguistic assistance during the preparation of this manuscript.
Authorship Contributions

Participated in research design: Zhou, Su, Gong.

Conducting experiments: Zhang, Lu.

Contributed new reagents or analytic tools: Zhou, Su.

Performed data analysis: Zhang, Zhou.

Wrote or contributed to the writing of the manuscript: Zhang, Zhou, Su.
References


Footnotes

a) This work was supported by a grant from the National Natural Science Foundation of China (81473194).

b) The authors declare that they have no competing interests.

Ethics approval and consent to participate

All procedures were conducted in strict accordance with the animal rights regulations.

Consent for publication

Not applicable.

Availability of data and materials

Not applicable.

c) Address reprint requests to

Dr. Ruibin Su
State Key Laboratory of Toxicology and Medical Countermeasures, Beijing Key Laboratory of Neuropsychopharmacology, Beijing Institute of Pharmacology and Toxicology, 27th Taiping Road, Beijing 100850, China.

Tel: +861066931621/01; fax: +861068211656.
**Figure Legends**

**Fig. 1 ABIN-1 in brain decreased morphine tolerance and dependence.** (A) Schematic of the experimental paradigm for the morphine-induced tolerance and naloxone-induced withdrawal test. (B, F) The % maximum possible effect (%MPE) of morphine analgesia following ABIN-1 overexpression (B, red lines) or knockdown (F, blue lines) in mice brains. (C, G) The naloxone-induced jumping counts following ABIN-1 overexpression (C, red bars) or knockdown (G, blue bars) in mice brains. (D) Schematic of experimental paradigm for morphine-induced conditioned place preference (CPP) test. (E, H) CPP score after ABIN-1 overexpression (E) or knockdown (H) in mice brains. The error bars indicate the means ± SD; the %MPE and CPP score results were analysed by two-way ANOVA followed by Bonferroni post hoc test; the jumping counts was analysed by one-way ANOVA followed by Bonferroni post-tests; * $P < 0.05$, **$P < 0.01$, ***$P < 0.001$, ABIN-1 vs. control; ##$P < 0.01$, Post-conditioning (Post-C) vs. Baseline; hotplate assay used female mice, n = 8; withdrawal assay used female mice, n=8; CPP test used male mice, n=7-8.

**Fig. 2 ABIN-1 interacts with β-arrestin2 and promotes β-arrestin2 ubiquitination and degradation.** (A) Colocalization of ABIN-1(red) and β-arrestin2 (green) in HEK293 cells. Bar, 10 μm, Pearson's R value: 0.74. The confocal microscopic images
are representative results from three independent experiments. (B) Immunoblot analysis showing the interaction between ABIN-1 and β-arrestin2 with or without DAMGO (10 μM) treatment using co-immunoprecipitation. (C) Immunoblot analysis showing the interaction between ABIN-1 and β-arrestin2 in Neuro 2A cells using co-immunoprecipitation. (D) Immunoblot analysis showing the ubiquitination of β-arrestin2 in HEK293 cells with ABIN-1 and MOR overexpression under DAMGO (10 μM) treatment following co-immunoprecipitation. (E) Immunoblot analysis showing levels of β-arrestin2 in Neuro 2A cells with overexpressed ABIN-1 following DAMGO (10 μM) treatment. The error bars indicate the means ± SD, two-way ANOVA followed by Bonferroni post hoc test, * P < 0.05, **P < 0.01, ABIN-1 vs vector, n = 5.

**Fig. 3 ABIN-1 inhibits the phosphorylation and internalization of MOR.** (A-B) Immunoblot analysis showing levels of phosphorylated MOR (phos MOR) and ERK (phos ERK) in MOR-CHO and MOR-ABIN-1-CHO cells treated with DAMGO (10 μM) for 0, 5, 30, and 60 min (A) or for 24, 36, or 48 h (B). (C) Immunoblot analysis showing levels of MOR on plasma membrane of MOR-CHO and MOR-ABIN-1-CHO cells treated with DAMGO (10 μM) at 30 min or 72 h of treatment. The error bars indicate the means ± SD, two-way ANOVA followed by Bonferroni post hoc test, * P < 0.05, **P < 0.01, ***P < 0.001, ABIN-1 vs. vector at the same time; ####P < 0.0001, compared with 0 min in MOR-CHO cells, n = 3-5.

**Fig. 4 β-arrestin2 is responsible for the ABIN-1-induced reduction of morphine**
tolerance. (A, C) The nociceptive threshold (A) and % MPE of analgesia (C) induced by chronic morphine treatment in ARRB2<sup>−/−</sup> mice with ABIN-1 overexpression. (B, D) The nociceptive threshold (B) and %MPE of analgesia (D) induced by chronic morphine treatment in ARRB2<sup>−/−</sup> mice with ABIN-1 knockdown. The error bars indicate the means ± SD; two-way ANOVA followed by Bonferroni post hoc test; ARRB2<sup>−/−</sup> control vs WT; *<i>P</i> < 0.05, **<i>P</i> < 0.01, ***<i>P</i> < 0.001, ****<i>P</i> < 0.0001; n = 5-6.
Table 1. Western blot antibodies

<table>
<thead>
<tr>
<th>Antibody</th>
<th>Reagent Company</th>
<th>Reagent Number</th>
<th>Proportion</th>
</tr>
</thead>
<tbody>
<tr>
<td>anti-MOR</td>
<td>Millipore</td>
<td>Cat# AB1580- I</td>
<td>1:500</td>
</tr>
<tr>
<td>anti-β-arrestin2</td>
<td>Life Spanbio Sciences</td>
<td>Cat#LS-B6008</td>
<td>1:1,000</td>
</tr>
<tr>
<td>Anti-FLAG M2</td>
<td>Sigma-Aldrich</td>
<td>F3165</td>
<td>1:5,000</td>
</tr>
<tr>
<td>Anti-ABIN-1</td>
<td>Cell Signalling Technology</td>
<td>Cat#4664</td>
<td>1:1,000</td>
</tr>
<tr>
<td>Anti-Myc</td>
<td>Cell Signalling Technology</td>
<td>Cat#2272</td>
<td>1:1,000</td>
</tr>
<tr>
<td>Anti-phos-MOR( Ser375)</td>
<td>Cell Signalling Technology</td>
<td>Cat#3451</td>
<td>1:1,000</td>
</tr>
<tr>
<td>Anti-ERK</td>
<td>Cell Signalling Technology</td>
<td>Cat#3857</td>
<td>1:1,000</td>
</tr>
<tr>
<td>Anti-phos-ERK</td>
<td>Cell Signalling Technology</td>
<td>Cat#9154</td>
<td>1:1,000</td>
</tr>
<tr>
<td>Anti-Na⁺-K⁺ATPase</td>
<td>Cell Signalling Technology</td>
<td>Cat#3010</td>
<td>1:1,000</td>
</tr>
<tr>
<td>Anti-UbP4D1</td>
<td>Santa Cruz Biotechnology</td>
<td>Cat#sc-8017,</td>
<td>1:500</td>
</tr>
<tr>
<td></td>
<td>Inc</td>
<td></td>
<td></td>
</tr>
<tr>
<td>anti-IgG</td>
<td>Santa Cruz Biotechnology</td>
<td>Cat#sc-2025</td>
<td>1 μg</td>
</tr>
<tr>
<td></td>
<td>Inc</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
Figure 1
Figure 2

### B

<table>
<thead>
<tr>
<th>Treatment</th>
<th>ABIN-1</th>
<th>β-arrin2</th>
<th>DAPI</th>
<th>Merge</th>
</tr>
</thead>
<tbody>
<tr>
<td>ABIN-1</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>+</td>
</tr>
<tr>
<td>Flag-β-arrin2</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>+</td>
</tr>
<tr>
<td>MOR</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>+</td>
</tr>
<tr>
<td>DAMGO</td>
<td>+</td>
<td></td>
<td></td>
<td>+</td>
</tr>
</tbody>
</table>

### C

<table>
<thead>
<tr>
<th>Treatment</th>
<th>Input</th>
<th>IP: Anti-β-arrin2</th>
<th>IP: IgG</th>
</tr>
</thead>
<tbody>
<tr>
<td>ABIN-1</td>
<td>+</td>
<td>+</td>
<td>+</td>
</tr>
<tr>
<td>β-arrin2</td>
<td>+</td>
<td>+</td>
<td>+</td>
</tr>
</tbody>
</table>

### D

<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>ABIN-1</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>+</td>
</tr>
<tr>
<td>Flag-β-arrin2</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>+</td>
</tr>
<tr>
<td>MOR</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>+</td>
</tr>
<tr>
<td>DAMGO</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>+</td>
</tr>
</tbody>
</table>

### E

<table>
<thead>
<tr>
<th>Treatment</th>
<th>Input</th>
<th>β-arrin2</th>
<th>Tubulin</th>
<th>ABIN-1</th>
</tr>
</thead>
<tbody>
<tr>
<td>ABIN-1</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>+</td>
</tr>
<tr>
<td>DAMGO</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>+</td>
</tr>
</tbody>
</table>

Fold change:

- **DAMGO (10 μM)**

- Vector
- ABIN-1

- **0 min**
- **30 min**
Figure 3